Catherine Shu
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment (NCT04625699) | Catherine Shu | 2022-12-01 |
| SGI-110 Plus Durvalumab/Tremelimumab in SCLC (NCT03085849) | Catherine Shu | 2017-12-15 |
Track Catherine Shu automatically
Every clearance here is in the API, with alerts when new ones post.